Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination

Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS-CoV-2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Teresa PY, Alejo, Jennifer L., Mitchell, Jonathan, Kim, Jake D., Abedon, Aura T., Karaba, Andrew H., Thomas, Letitia, Levan, Macey L., Garonzik-Wang, Jacqueline M., Avery, Robin K., Pekosz, Andrew, Clarke, William A., Warren, Daniel S., Tobian, Aaron A.R., Massie, Allan B., Segev, Dorry L., Werbel, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111240/
https://www.ncbi.nlm.nih.gov/pubmed/35429211
http://dx.doi.org/10.1111/ajt.17061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111240/
https://www.ncbi.nlm.nih.gov/pubmed/35429211
http://dx.doi.org/10.1111/ajt.17061

Ejemplares similares